Background {#Sec1}
==========

The skin consists of the outer epidermis, beneath which are the dermis and subcutaneous tissue. Epidermal keratinocytes undergo a tightly regulated program of proliferation and differentiation leading to formation of the stratified epidermis, which consists of four layers including the stratum basale (SB), the stratum spinosum (SS), the stratum granulosum (SG), and the stratum corneum (SC) from the inside to the outside. For survival in a dry terrestrial environment, the epidermis constitutes a life-sustaining skin barrier, which not only prevents water loss (inside-out barrier), but also protects against invasion of environmental substances or microorganisms (outside-in barrier) \[[@CR1]\]. In the uppermost SC, corneocytes are embedded in a lipid-rich extracellular matrix that forms lamellar membranes composed of ceramides, cholesterol, and fatty acids in a mildly acidic environment \[[@CR2]\]. The epidermis also has immunologic functions, protecting the skin from ultraviolet damage via pigmentation of melanocytes and from external harmful stimuli by releasing various bioactive factors such as cytokines, chemokines, DAMPs (danger-associated molecular patterns), and lipid mediators, which relay signals to specialized immune cells residing in the epidermis and dermis \[[@CR3]\].

Another important component of the skin is the hair follicle, whose morphogenesis is regulated by interactions between epidermal keratinocytes committed to hair follicle differentiation and dermal fibroblasts committed to formation of the dermal papilla of developing hair follicles \[[@CR4]\]. These epithelial-mesenchymal interactions culminate in the formation of the hair shaft, which is surrounded by the multilayered inner root sheath and outer root sheath, the latter comprising an outermost concentric layer of keratinocytes. Hair follicles undergo repeated cycles of growth (anagen), regression (catagen), and rest (telogen) during their life span, representing one of the most regenerative organs in the body. Within the apex of the follicle are sebaceous glands, which produce sebum. The adipocyte layer within the hypodermis also constitutes a significant compartment of the skin, contributing to hair follicle activation \[[@CR5]\], skin regeneration \[[@CR6]\], and cold-induced adaptive thermogenesis \[[@CR7]\].

Lipids play fundamental roles in skin physiology and pathology. Dysregulated production of polyunsaturated fatty acid (PUFA)- or lysophospholipid-derived lipid mediators can be linked to skin disorders including alopecia, inflammation, and cancer. For instance, arachidonic acid (AA; ω6 C20:4)-derived lipid mediators such as prostaglandins (PGs) and leukotrienes (LTs) have diverse roles in immune responses and keratinocyte activation \[[@CR8], [@CR9]\], eicosapentaenoic acid (EPA; ω3 C20:5)- or docosahexaenoic acid (DHA; ω3 C22:6)-derived resolvins attenuate skin immune responses \[[@CR10], [@CR11]\], and lysophosphatidic acid (LPA) controls hair homeostasis \[[@CR12], [@CR13]\]. Apart from these signaling lipids, linoleic acid (LA; ω6 18:2), by far the most abundant PUFA in the epidermis, is esterified to the ω-hydroxyl group of ultra-long chain fatty acids in ceramides, thus forming ω-*O*-acylceramide, a structural lipid that is essential for skin barrier function \[[@CR14]\]. Fatty acids have also been proposed to be important for SC acidification \[[@CR15]\].

Release of fatty acids and lysophospholipids from glycerophospholipids (phospholipids hereafter) is catalyzed by phospholipase A~2~ (PLA~2~) enzymes, which are classified into several families as shown in Table [1](#Tab1){ref-type="table"} \[[@CR16]\]. Until recently, however, it has remained obscure as to which PLA~2~ subtype(s) is important in the skin, which lipid species serve as the substrates and products for the PLA~2~(s), and how the PLA~2~-driven lipid metabolites affect skin pathophysiology. In this review, we highlight the distinct roles of several secreted PLA~2~s (sPLA~2~s) and the patatin-like phospholipase PNPLA1, whose functions have been revealed by recent studies using gene-manipulated (transgenic and knockout) mice in combination with mass spectrometry-based analytical techniques referred to collectively as lipidomics. Importantly, these enzymes are linked to unique lipid pathways distinct from canonical AA metabolism. The localizations and functions of particular PLA~2~s in the skin, as described in this review, are summarized in Fig. [1](#Fig1){ref-type="fig"}.Table 1The classification of PLA~2~ family. sPLA~2~, cPLA~2~, and iPLA~2~/PNPLA are the original big three among the PLA~2~ family. The sPLA~2~ family contains 10 catalytically active isoforms (IB, IIA, IIC, IID, IIE, IIF, III, V, X, XIIA) and 1 inactive isoform (XIIB) in mammals. The cPLA~2~ family comprises 6 isoforms (α-ζ). The human genome encodes 9 iPLA~2~ enzymes. These enzymes are now more generally referred to as PNPLA (1--9). In this review, the biological roles of particular PLA~2~s in the context of skin homeostasis and diseases were describedFamilyIsoformsGene nameCommon nameAliasEnzyme propertysPLA~2~11PLA2G1BsPLA~2~-IBPancreatic sPLA~2~PLA~2~PLA2G2AsPLA~2~-IIANon-pancreatic sPLA~2~PLA~2~PLA2G2CsPLA~2~-IICPLA~2~PLA2G2DsPLA~2~-IIDPLA~2~PLA2G2EsPLA~2~-IIEPLA~2~PLA2G2FsPLA~2~-IIFPLA~2~PLA2G3sPLA~2~-IIIPLA~2~PLA2G5sPLA~2~-VPLA~2~PLA2G10sPLA~2~-XPLA~2~PLA2G12AsPLA~2~-XIIAPLA~2~PLA2G12BsPLA~2~-XIIBInactivecPLA~2~6PLA2G4AcPLA~2~αPLA~2~PLA2G4BcPLA~2~βPLA~1~/A~2~PLA2G4CcPLA~2~γPLA~2~, transacylase, lysopholipasePLA2G4DcPLA~2~δPLA~1~/A~2~PLA2G4EcPLA~2~εPLA~1~/A~2~, *N-*acyltransferasePLA2G4FcPLA~2~ζPLA~1~/A~2~iPLA~2~/PNPLA9PNPLA1TransacylasePNPLA2iPLA~2~ζATGLTG lipasePNPLA3iPLA~2~εADPNTG lipase, acyltransferase, restiny-esteryl lipasePNPLA4iPLA~2~ηGS2Retinyl-esteryl lipase?PNPLA5GS2LTG lipasePNPLA6iPLA~2~δNTELysophospholipasePNPLA7NRELysophospholipasePNPLA8iPLA~2~γPLA~1~/A~2~PNPLA6iPLA~2~βPNPLA9PLA~2~Fig. 1Expressions and functions of various PLA~2~s in mouse skin. sPLA~2~-IIF is localized in the suprabasal epidermis and produces P-LPE, which promotes epidermal hyperplasic diseases such as psoriasis and skin cancer. Epidermal sPLA~2~-IIF expression and thereby P-LPE production are augmented by IL-17A and IL-22 supplied by γδ T and Th17 cells in psoriasis. sPLA~2~-IIE is localized in hair follicles in synchrony with the growing phase (anagen) of hair cycling and may regulate hair homeostasis. sPLA~2~-IID is constitutively expressed in DCs and M2 macrophages in regional LNs and produces ω3 PUFA-derived anti-inflammatory lipid mediators, which put a brake on Th1 or Th17 immunity, thereby sequestering CHS and psoriasis and promoting skin cancer. PNPLA1 is expressed in the border of SG and SC, where it produces ω-*O*-acylceramide that is essential for skin barrier function. For details, please see the text

sPLA~2~-IIF, an epidermal sPLA~2~ {#Sec2}
=================================

The sPLA~2~ family consists of 11 isoforms with distinct substrate specificities and tissue distributions \[[@CR17], [@CR18]\]. Historically, several sPLA~2~s have been detected in mouse and human skin, but by using semi-quantitative RT-PCR and immunoblotting which have uncertain specificity \[[@CR19]--[@CR23]\]. sPLA~2~s have also been suggested to supply fatty acids for formation of the SC acid mantle, a hypothesis that stems primarily from the observation that SC acidity is perturbed by non-specific sPLA~2~ inhibitors \[[@CR15], [@CR23]--[@CR25]\]. However, the molecular identity of any particular sPLA~2~(s) that participates in skin homeostasis and diseases has remained unclear until recently. Now, it has become obvious that sPLA~2~-IIF is a bona fide "epidermal sPLA~2~" that controls keratinocyte differentiation, hyperproliferation, and function \[[@CR26]\].

Among the group II subfamily sPLA~2~s (which include sPLA~2~-IIA, sPLA~2~-IIC, sPLA~2~-IID, sPLA~2~-IIE, sPLA~2~-IIF, and sPLA~2~-V), sPLA~2~-IIF has several unique features \[[@CR27], [@CR28]\]. sPLA~2~-IIF has a uniquely long C-terminal extension that is proline-rich and contains a single cysteine, which raises the possibility that it might form a covalent homodimer, although this hypothesis has not been confirmed. In contrast to other group II subfamily sPLA~2~s that are basic proteins and catalytically active at neutral to mildly basic pH, sPLA~2~-IIF is an acidic protein (pI \~ 5.8) and retains its full enzymatic activity even at mildly acidic pH. This property may be related to the distribution of this enzyme in the upper epidermis (see below), which has a mildly acidic environment \[[@CR15]\]. Furthermore, sPLA~2~-IIF is more hydrophobic than other sPLA~2~s, and probably because of this, it has a unique ability to penetrate and disrupt lipid monolayers and bilayers in vitro; when added exogenously, it rapidly enters the cells in an endocytosis-independent manner to form unusual aggregates \[[@CR29]\]. Moreover, when overexpressed, sPLA~2~-IIF also tends to aggregate within the cells and can undergo *N*-glycosylation at three positions, possibly increasing its water solubility and thereby decreasing the unusual accumulation of sPLA~2~-IIF aggregates. However, it remains unknown whether or not endogenous sPLA~2~-IIF (or any other sPLA~2~s) is *N*-glycosylated in vivo. In a PLA~2~ enzyme assay using a phospholipid mixture extracted from mouse skin as a substrate (natural membrane assay \[[@CR30]\]), a physiologically relevant concentration of sPLA~2~-IIF preferentially hydrolyzes phosphatidylethanolamine (PE; particularly plasmalogen-type PE) containing PUFAs (particularly DHA) to yield plasmalogen-type lysoPE (P-LPE) and DHA in preference to AA \[[@CR26]\]. Therefore, although sPLA~2~-IIF is capable of releasing AA when overexpressed in mammalian cells at super-physiological levels \[[@CR31]\], it may mobilize lipid metabolites separately from canonical AA metabolism under physiological conditions (see below).

It is now obvious that sPLA~2~-IIF is a major sPLA~2~ expressed in mouse epidermis, where it is distributed in the suprabasal SS, SG, and SC layers \[[@CR26]\]. Developmental expression of *Pla2g2f* in mouse skin is far greater than that of other sPLA~2~s (except for *Pla2g2e*, see below), gradually increasing before birth to reach a maximum level by P5 (Fig. [2](#Fig2){ref-type="fig"}a). sPLA~2~-IIF expression is markedly induced during Ca^2+^-induced differentiation and also robustly upregulated in primary keratinocytes following stimulation with the Th17 cytokines IL-22 and IL-17A. Moreover, sPLA~2~-IIF is induced in mouse skin treated with imiquiod, an inducer of experimental psoriasis, and also highly expressed in the hyperplasic epidermis of patients with psoriasis. Strikingly, global or skin-specific transgenic mice overexpressing mouse sPLA~2~-IIF (*Pla2g2f*-TG) spontaneously develop psoriasis-like epidermal hyperplasia and alopecia, with increased expression of various psoriasis markers such as S100A9 and IL-36α \[[@CR26]\], suggesting that increased expression of this sPLA~2~ alone could trigger psoriasis.Fig. 2Skin abnormalities in knockout and transgenic mice for various sPLA~2~s. **a** Developmental expression of sPLA~2~s in mouse skin as assessed by quantitative RT-PCR. *Pla2g2f* is expressed throughout the peri- to postnatal period, while the periodic pattern of *Pla2g2e* expression coincides with the hair cycle, which involves repeated cycles of growth (anagen; P0--15), regression (catagen; P15--20), rest (telogen; P20--25), and re-growth (the next anagen; beyond P25). A representative result of two independent experiments is shown. **b** Expression of several keratinocyte markers in *Pla2g2f*^+/+^ and *Pla2g2f*^−/−^ keratinocytes cultured for the indicated periods with 1 mM Ca^2+^ (*n* = 4, mean ± SEM, \**P* \< 0.05). *Pla2g2f* deficiency impairs the induction of *S100a9* (an activation marker) and *Krt1* (an SS marker), but not *Krt14* (a SB marker), suggesting that sPLA~2~-IIF regulates keratinocyte differentiation and activation. **c** Microarray profiling (Agilent Technologies) of genes associated with hair follicles and epidermis in *Pla2g2f*-TG (IIF-TG) or *PLA2G10*-TG (X-TG) mice relative to WT mice. In both strains, similar sets of genes are decreased in hair follicles (green), which reflects alopecia, and increased in the epidermis (red), which reflects epidermal hyperplasia. **d** Hematoxylin and eosin staining of skins from WT and *PLA2G10*-TG mice at P25. Hair follicle distortion and epidermal thickening are evident in the TG mice. IRS, inner root sheath. All animal experiments were performed in accordance with the protocols approved by the Institutional Animal Care and Use Committees in accordance with the Japanese Guide for the Care and Use of Laboratory Animals

In a basal state, *Pla2g2f*^−/−^ mice have mild abnormalities in the skin (particularly the abdominal skin, probably because it is continuously exposed to friction against the ground surface), as revealed by a fragile stratum corneum with modest perturbation of skin barrier function and acidity \[[@CR26]\]. After tape stripping of the SC, *Pla2g2f*^−/−^ mice display delayed recovery from the epidermal barrier perturbation \[[@CR23]\]. In primary culture, keratinocytes from *Pla2g2f*^−/−^ mice fail to differentiate and become properly activated (Fig. [2](#Fig2){ref-type="fig"}b), and similar defects are evident when WT keratinocytes are treated with a pan-sPLA~2~ inhibitor or an sPLA~2~-IIF-directed siRNA. Most importantly, in pathological settings, *Pla2g2f*^−/−^ mice are protected from epidermal hyperplasia and associated inflammation in models of Th17-dependent psoriasis and Th1-dependent contact hypersensitivity (CHS) \[[@CR26]\]. Consistent with this, *Pla2g2f* deficiency in keratinocytes markedly impairs the induction of several psoriasis markers in response to IL-17A or IL-22. Moreover, *Pla2g2f*^−/−^ mice are also protected from skin carcinogenesis, whereas *Pla2g2f*-TG mice conversely develop larger skin tumors than WT mice \[[@CR26]\]. Mechanistically, sPLA~2~-IIF preferentially hydrolyzes plasmalogen-type PE secreted from keratinocytes to yield P-LPE, a unique lysophospholipid that facilitates the differentiation and activation of keratinocytes, leading to exacerbation of epidermal hyperplasia and inflammation. Indeed, the skin levels of P-LPE are correlated well with those of sPLA~2~-IIF expression in several skin disease models, and topical application of P-LPE to *Pla2g2f*^−/−^ skin in vivo or supplementation of *Pla2g2f*^−/−^ keratinocytes with P-LPE ex vivo restores the psoriasis-related phenotypes.

Taken together, these results indicate that sPLA~2~-IIF promotes epidermal hyperplasic diseases including psoriasis and skin cancer and that P-LPE, a primary sPLA~2~-IIF product, represents a biomarker and bioactive lipid that reflects the expression and function of sPLA~2~-IIF. Given that sPLA~2~-IIF is expressed in the epidermis rather specifically and that *Pla2g2f*^−/−^ mice display more profound skin phenotypes in diseases than in homeostasis, inhibition of this particular sPLA~2~ may be useful for treatment of psoriasis, skin cancer, or other conditions involving epidermal hyperplasia. It remains to be determined, however, whether sPLA~2~-IIF-driven P-LPE would act on keratinocytes through a specific receptor or through other mechanism(s). It is also possible that DHA, another sPLA~2~-IIF-driven product, would be metabolized to certain metabolites that could affect skin homeostasis, since DHA or its pro-resolving metabolites can facilitate skin wound healing, suppress psoriasis, and prevent neoplastic transformation of keratinocytes \[[@CR32]--[@CR34]\].

sPLA~2~-IIE, a hair follicular sPLA~2~ {#Sec3}
======================================

Although sPLA~2~-IIE is not substantially expressed in the epidermis, it is a major "hair follicular sPLA~2~" in mice, being expressed in hair follicles in synchrony with hair cycling \[[@CR35]\]. Thus, during the anagen phase, sPLA~2~-IIE is distributed in companion cells of the outer root sheath and cuticular cells of the inner root sheath in growing hair follicles. At P10--15, when hair follicles are maximally developed in the initial hair cycle, the expression of sPLA~2~-IIE becomes maximal, even exceeding that of sPLA~2~-IIF in the whole mouse skin (Fig. [2](#Fig2){ref-type="fig"}a). In contrast, during the catagen to telogen phase, when hair follicles regress, sPLA~2~-IIE expression promptly decreases to a negligible level, and then rises again in correlation with entry into the next anagen.

*Pla2g2e*^−/−^ mice exhibit mild skin abnormalities with perturbation of hair follicle ultrastructure and modest changes in the steady-state expression of a subset of skin genes. Lipidomics analysis has revealed that sPLA~2~-IIE mobilizes various unsaturated fatty acids and LPE species (both acyl and plasmalogen forms) in mouse skin, in agreement with the in vitro substrate selectivity of this enzyme \[[@CR35]\]. Although several lipid mediators such as PGD~2~ and LPA play crucial roles in hair homeostasis \[[@CR13], [@CR36]\], the hair phenotypes observed in mice lacking sPLA~2~-IIE appear to be much milder than those in mice lacking synthases or receptors for these lipid mediators. Therefore, it still remains unclear which lipid metabolites mobilized by sPLA~2~-IIE are involved in the regulation of hair follicle homeostasis. Notably, in contrast to *Pla2g2f*^−/−^ mice, *Pla2g2e*^−/−^ mice do not exhibit psoriasis-related phenotypes \[[@CR35]\], implying that these two skin sPLA~2~s---hair follicular sPLA~2~-IIE and epidermal sPLA~2~-IIF---play non-redundant roles in distinct compartments of mouse skin, underscoring the functional diversity of multiple sPLA~2~s in the coordinated regulation of skin homeostasis and diseases.

Since humans are essentially furless, it is unclear whether sPLA~2~-IIE is also expressed and plays certain roles in human hair follicles. It should be noted that although sPLA~2~-IIE expression is induced in several mouse tissues during inflammation \[[@CR37]\], it is hardly detected in human tissues, representing a notable species difference. As sPLA~2~-IIA, the closest homolog of sPLA~2~-IIE, is highly induced during inflammation in humans \[[@CR37]\], it has been proposed that the functions of sPLA~2~-IIA in humans might be compensated by sPLA~2~-IIE in mice \[[@CR38]\].

sPLA~2~-IID, a resolving sPLA~2~ {#Sec4}
================================

While sPLA~2~-IIF and sPLA~2~-IIE are abundantly expressed in keratinocytes of the upper epidermis and hair follicles, respectively (see above), sPLA~2~-IID is barely detectable in mouse skin. Instead, sPLA~2~-IID is abundantly expressed in dendritic cells (DCs) and M2-like macrophages in secondary lymphoid organs such as the spleen and lymph nodes (LNs) of mice and humans \[[@CR39], [@CR40]\]. The expression of sPLA~2~-IID is downregulated, rather than upregulated, following inflammatory stimuli \[[@CR39], [@CR41]\]. This property is unique among the sPLA~2~ isoforms and probably reflects its role as a "resolving sPLA~2~" that counteracts inflammation \[[@CR18], [@CR39]\]. Despite the low expression of sPLA~2~-IID in skin, *Pla2g2d* deficiency leads to exacerbation of CHS and psoriasis. This is most likely because sPLA~2~-IID attenuates adaptive immunity in the LNs, thereby sequestering Th1 and Th17 immune responses \[[@CR39], [@CR40]\].

In a model of CHS, the resolution of inflammation in the skin and regional LNs is delayed in *Pla2g2d*^−/−^ mice \[[@CR39]\]. In this state, expression of the Th1 cytokines IFN-γ and IL-12 is robustly elevated in the LNs. Likewise, in a model of psoriasis, *Pla2g2d*^−/−^ mice display more severe epidermal hyperplasia than do *Pla2g2d*^+/+^ mice, with increased IL-17A^+^ or IL-22^+^ T cells in the affected skin and LNs \[[@CR40]\]. Furthermore, DCs isolated from *Pla2g2d*^−/−^ mice are hyper-activated even in the absence of stimulation. Mechanistically, sPLA~2~-IID in the LNs constitutively hydrolyzes PUFA-containing PE species (likely in microparticle membranes) to mobilize ω3 PUFA-derived anti-inflammatory lipid mediators, which can put a brake on DC-committed adaptive immunity. Indeed, the steady-state levels of ω3 PUFAs and their metabolites, such as DHA-derived resolvin D1 (RvD1), are markedly reduced in the LNs of *Pla2g2d*^−/−^ mice relative to *Pla2g2d*^+/+^ mice. Conversely, *Pla2g2d*-TG mice display milder inflammation in the CHS and psoriasis models, with increased levels of ω3 PUFA metabolites \[[@CR40]\]. ω3 PUFA-derived resolvins and maresins suppress acquired immunity by attenuating migration and activation of DCs, antigen presentation to T cells, and IgE class switching in B cells \[[@CR10], [@CR39], [@CR42], [@CR43]\]. Moreover, these ω3 PUFA-derived lipid mediators have the ability to facilitate the polarization of anti-inflammatory M2 macrophages \[[@CR44], [@CR45]\], consistent with the fact that fewer M2 macrophages are present in the LNs of *Pla2g2d*^−/−^ mice \[[@CR40]\].

On the other hand, the beneficial role of sPLA~2~-IID in counteracting harmful Th1/Th17 immune responses can be conversely disadvantageous in some situations such as host defense against infection and cancer \[[@CR40], [@CR46]\]. Indeed, sPLA~2~-IID promotes, rather than prevents, the development of skin tumors, likely because it attenuates anti-tumor Th1 immunity. Accordingly, *Pla2g2d*^−/−^ mice are protected against skin carcinogenesis, with increased numbers of tumor-suppressing cytotoxic T cells and M1 macrophages \[[@CR40]\]. Thus, the immunosuppressive function of sPLA~2~-IID provides "good" or "bad" outcomes in distinct disease settings, protecting against skin inflammation and exacerbating skin cancer. In the latter context, specific inhibition of sPLA~2~-IID in patients with certain types of cancer would be a potentially attractive therapeutic intervention for restoration of immunological functions, a concept reminiscent of "immune checkpoint" therapy.

Recalling sPLA~2~-IIA and sPLA~2~-X: a matter of species difference {#Sec5}
===================================================================

As in the case of transgenic mice overexpressing sPLA~2~-IIF \[[@CR26]\], those overexpressing human sPLA~2~-IIA or sPLA~2~-X (*PLA2G2A*-TG and *PLA2G10*-TG, respectively) also develop alopecia and epidermal hyperplasia, accompanied by cyst formation, sebaceous gland hyperplasia, and a disturbed hair stem cell fate (Fig. [2](#Fig2){ref-type="fig"}c, d) \[[@CR47]--[@CR49]\]. However, since neither sPLA~2~-IIA nor sPLA~2~-X is endogenously detected in mouse skin at a substantial level \[[@CR26], [@CR50]\], the intrinsic roles of these two sPLA~2~s in the skin have remained elusive. The discovery of sPLA~2~-IIF as a bona fide "epidermal sPLA~2~" in mice \[[@CR26]\] has led to speculation that the skin phenotypes observed in *PLA2G2A*-TG or *PLA2G10*-TG mice may reflect the fact that sPLA~2~-IIA or sPLA~2~-X mimics the intrinsic actions of sPLA~2~-IIF when artificially overexpressed in the skin, or that endogenous sPLA~2~-IIF is upregulated in the hyperplasic epidermis of these transgenic mice. In support of the latter idea, the skin of *PLA2G10*-TG mice has elevated expression of sPLA~2~-IIF, with increased hydrolysis of DHA-containing PE species \[[@CR26], [@CR49]\], and microarray gene profiling of the skin reveals similar changes in gene expression between *PLA2G2F*-TG and *PLA2G10*-TG mice (Fig. [2](#Fig2){ref-type="fig"}c).

However, considering the species difference between mice and humans, as already pointed out for the relationship between sPLA~2~-IIA and sPLA~2~-IIE (see above), it seems important to reconcile the expression of sPLA~2~-IIA or sPLA~2~-X in human keratinocytes. Indeed, beyond the uncertainty regarding the specificity of the detection methods employed, previous studies have demonstrated the expression of various sPLA~2~s in human keratinocytes \[[@CR21]\]. Moreover, under the assumption that sPLA~2~-X is expressed in keratinocytes, exogenously added sPLA~2~-X can stimulate dendricity and pigmentation of human melanocytes through a mechanism dependent upon lysophosphatidylcholine \[[@CR51]\]. We therefore reevaluated the expression of sPLA~2~s in human keratinocytes by quantitative RT-PCR. As in mouse primary epidermal keratinocytes (MPEKs) (Fig. [3](#Fig3){ref-type="fig"}a), *PLA2G2F* was induced following Ca^2+^-induced differentiation, whereas other sPLA~2~s including *PLA2G1B*, *PLA2G2A*, *PLA2G2D*, *PLA2G2E*, *PLA2G5*, and *PLA2G10* were barely detectable, in human primary epidermal keratinocytes (HPEKs) (Fig. [3](#Fig3){ref-type="fig"}b). In contrast, in the transformed human keratinocyte cell line HaCaT, there was robust Ca^2+^-induced upregulation of *PLA2G2A* and *PLA2G10*, which was even greater than that of *PLA2G2F* as well as *PLA2G5* (Fig. [3](#Fig3){ref-type="fig"}c). These results suggest that not only sPLA~2~-IIF, but also sPLA~2~-IIA, sPLA~2~-X, and possibly sPLA~2~-V can be expressed in transformed, rather than normal, human keratinocytes. Thus, although it is possible that sPLA~2~-IIA and sPLA~2~-X might participate in certain forms of skin pathology such as cancer, it is nonetheless likely that sPLA~2~-IIF is the primary sPLA~2~ acting in the epidermis of both mice and humans under physiological conditions. This is reminiscent of the fact that sPLA~2~-V is upregulated in the transformed mouse macrophage cell line P388D~1~ \[[@CR52]\], whereas it is not induced, but rather downregulated, in primary mouse macrophages \[[@CR38]\], after stimulation with LPS or zymosan. Therefore, caution should be exercised when interpreting the data obtained from studies using transformed cell lines.Fig. 3Expression of sPLA~2~s in mouse and human keratinocytes. Quantitative RT-PCR of various sPLA~2~s in MPEKs (**a**), HPEKs (**b**), and HaCaT cells (**c**) that were cultured for the indicated periods with 1 mM Ca^2+^ (*n* = 4, mean ± SEM, \**P* \< 0.05). *PLA2G2F* is the dominant sPLA~2~ expressed in MPEKs and HPEKs, whereas *PLA2G2A* \> *PLA2G10* \> *PLA2G2F* \> *PLA2G5* are expressed in HaCaT cells

PNPLA1, an ω-*O*-acylceramide synthase (transacylase) {#Sec6}
=====================================================

The epidermis contains a unique class of ceramides with ω-hydroxy ultra-long chain fatty acids (C30--C36) esterified specifically with LA. This particular ceramide class is called ω-*O*-acylceramide, a key lipid component essential for skin barrier function \[[@CR53]\]. The unique structure and high hydrophobicity of ω-*O*-acylceramide are important for the organization and function of lipid lamellae in the SC, where this unique lipid serves as a "molecular rivet" that connects adjacent lamellar membrane structures. ω-*O*-acylceramide also acts as a precursor of protein-bound ceramides for formation of the cornified lipid envelope, where a lipid monolayer is covalently bound to the cornified envelope. A series of recent studies on patients with congenital ichthyosis have revealed that many of the causal genes are related to the biosynthesis and metabolism of ω-*O*-acylceramide \[[@CR54]\]. The entire picture of ω-*O*-acylceramide metabolism has been comprehensively summarized in other recent reviews \[[@CR14], [@CR55]\].

A recent breakthrough in this research area has been the identification of PNPLA1, a member of the iPLA~2~ family, as a long-sought ω-*O*-acylceramide synthase, whose genetic mutations in humans and dogs cause congenital ichthyosis \[[@CR56]\] and deletion in mice leads to neonatal death due to excessive transepidermal dehydration resulting from severe skin barrier defect \[[@CR57]--[@CR59]\]. PNPLA1 catalyzes the unique transacylase reaction, whereby the LA moiety cleaved from triacylglycerol through the lipase-like reaction of this enzyme is directly transferred to the ω-hydroxy moiety of ultra-long chain fatty acid in ceramide (ω-*O*-hydroxyceramide), with the ω-hydroxy group, instead of water, serving as an acyl (linoleoyl) acceptor \[[@CR60]\]. Thus, on the basis of PLA~2~ biology, PNPLA1 is particularly unique in that it (i) is involved in the metabolism of sphingolipids rather than glycerophospholipids, (ii) catalyzes transacylation rather than hydrolysis of target substrates, and (iii) recognizes the specific lipoquality of LA and ultra-long chain fatty acids.

Of additional note, PLA2G15 (also known as lysosomal PLA~2~ or LPLA2) has the capacity to catalyze the biosynthesis of 1-*O*-acylceramide through transacylation of fatty acid from the *sn*-2 position of phospholipid to the 1-hydroxy group of ceramide \[[@CR61]\]. 1-*O*-acylceramide is a natural component of human and mouse epidermis \[[@CR62]\]. However, the biological importance of this unique lipid and the contribution of PLA2G15 to its biosynthesis in vivo are unclear.

Conclusions {#Sec7}
===========

Healthy skin depends on a unique lipid profile to form a barrier that confers protection and prevents excessive water loss, aids cell-cell communication, and regulates cutaneous homoeostasis and inflammation. Alterations in the cutaneous lipid profile often have severe consequences for skin health and have been implicated in various skin diseases. Recent developments in lipidomics technologies now allow in-depth qualitative and quantitative investigation of a wide variety of cutaneous lipids, providing insight into their roles and mechanistic actions \[[@CR63]\]. Cross-communication between various types of bioactive lipids suggests that their cutaneous activities should be considered as part of a wider metabolic network that can be targeted to maintain skin health, control inflammation, and improve skin pathologies \[[@CR64]\].

Given that PLA~2~s are crucial enzymes for the control of lipoquality, it is of particular importance to understand the expression and function of each PLA~2~ in a specific skin niche. In addition to sPLA~2~s and PNPLA1, which we have focused on here, several biochemical and pharmacological studies have suggested potential contributions of other PLA~2~s such as cytosolic PLA~2~s (cPLA~2~α and cPLA~2~δ) to skin inflammation \[[@CR65]--[@CR68]\], although these findings should be confirmed by genetic studies using knockout mice for these enzymes. Our preliminary study has revealed that several other PLA~2~s are also expressed in different cell populations and may play distinct roles in skin homeostasis and inflammation. Thus, unveiling the entire view of lipid metabolism driven by various forms of PLA~2~s will support translational studies exploring the involvement of lipids in skin health and disease.
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